Status: Not yet recruiting
A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia
This is a Phase I, single-arm, open-label, dose-escalation and dose-expansion study. The primary objective is to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of YTS109 START T-cell therapy in patients with autoimmune hemolytic anemia who have failed ≥3 lines of therapy.
Participants needed: 7
Trial details
Phase: Phase 1Age: 12+Biological sex: AllType: InterventionalSponsor: Institute of Hematology & Blood Diseases Hospital, ChinaUpdated: Jan 13, 2025
Eligibility criteria
Age ≥12 years, regardless of gender. [+6]
Diagnosis of lymphoproliferative tumor [+17]